Tanja Egener-Kuhn

Biographie

Tanja Egener-Kuhn studied Biology in Marburg (Germany) and Oxford (UK) and received her PhD in Molecular Biology from the Max-Planck-Institute for Terrestrial Microbiology in 1998. She continued her postdoctoral research in plant biotechnology in a joint-initiative between the Albert-Ludwigs-University of Freiburg and the German chemistry leader BASF. Expanding her expertise to the human biotechnology, she joined the Laboratoire de Biotechnologie Moléculaire (LBTM) of the University of Lausanne in 2003 before leaving the lab bench and orienting toward management of academic structures. She coordinated national and regional centers like the NCCBI (National Competence Center for Biomedical Imaging), and the CIBM (Center for Biomedical Imaging) and recently obtained a DAS in 'Management of non-profit organizations' from the Geneva School of Economics and Management. In 2021 Dr. Tanja Egener-Kuhn joined the EPFL's School of Basic Sciences as Deputy to the Dean.

À propos de ce résultat

Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.

Unités associées (5)

Unités associées

Chargement

Cours enseignés par cette personne

Chargement

Domaines de recherche associés

Chargement

Publications associées (2)

Publications associées

Chargement

Personnes menant des recherches similaires

Chargement

Protein-Binding Microarray Analysis of Tumor Suppressor AP2 alpha Target Gene Specificity

Tanja Egener-Kuhn, Luigino Grasso, Jan Kerschgens, Hans-Anton Lehr, Nicolas Mermod, Horst Vogel

Cheap and massively parallel methods to assess the DNA-binding specificity of transcription factors are actively sought, given their prominent regulatory role in cellular processes and diseases. Here we evaluated the use of protein-binding microarrays (PBM) to probe the association of the tumor suppressor AP2 alpha with 6000 human genomic DNA regulatory sequences. We show that the PBM provides accurate relative binding affinities when compared to quantitative surface plasmon resonance assays. A PBM-based study of human healthy and breast tumor tissue extracts allowed the identification of previously unknown AP2 alpha target genes and it revealed genes whose direct or indirect interactions with AP2 alpha are affected in the diseased tissues. AP2 alpha binding and regulation was confirmed experimentally in human carcinoma cells for novel target genes involved in tumor progression and resistance to chemotherapeutics, providing a molecular interpretation of AP2 alpha role in cancer chemoresistance. Overall, we conclude that this approach provides quantitative and accurate assays of the specificity and activity of tumor suppressor and oncogenic proteins in clinical samples, interfacing genomic and proteomic assays.

Public Library of Science2011

Chargement

Protein-binding microarrays: probing disease markers at the interface of proteomics and genomics

Tanja Egener-Kuhn, Jan Kerschgens, Nicolas Mermod

DNA-binding proteins mediate a variety of crucial molecular functions, such as transcriptional regulation and chromosome maintenance, replication and repair, which in turn control cell division and differentiation. The roles of these proteins in disease are currently being investigated using microarray-based approaches. However, these assays can be difficult to adapt to routine diagnosis of complex diseases such as cancer. Here, we review promising alternative approaches involving protein-binding microarrays (PBMs) that probe the interaction of proteins from crude cell or tissue extracts with large collections of synthetic or natural DNA sequences. Recent studies have demonstrated the use of these novel PBM approaches to provide rapid and unbiased characterization of DNA-binding proteins as molecular markers of disease, for example cancer progression or infectious diseases.

2009

Chargement